City of Hope doctors present new research on bone marrow transplants, immunotherapy and other blood cancer treatments

CONTACT
Letisia Marquez
(626) 476-7593
lemarquez@coh.org
 
Data will be presented at virtual American Society of Hematology (ASH) Annual Meeting Dec. 5 to 8 
 
DUARTE, Calif. — City of Hope announced today that it will present data on new findings on bone marrow transplants, immunotherapies and other blood cancer treatments at ASH 62nd Annual Meeting and Exposition on Dec. 5 to 8, a virtual event.  
 
City of Hope is addressing some of the hardest-to-treat cancers by accelerating innovative clinical research approaches. The comprehensive cancer center was a pioneer in bone marrow and stem cell transplants — and the transplantation program is now one of the largest and most successful programs of its kind in the U.S. For the 15th year in a row, the Center for International Blood & Marrow Transplant Research has ranked City of Hope as providing exceptional care and strong clinical outcomes for patients who received bone or stem cell transplants; it is the only cancer center to hold this distinction.
 
During the ASH virtual conference, City of Hope researchers will make presentations on the following and other data:
 
Publication Number: 298
Type: Oral
Session Name: 732. Clinical Allogeneic Transplantation Results III
Session Date and Time: Saturday, Dec. 5, 2020, 2 to 3:30 p.m. ET
Presentation Time: 2:30 p.m.
Presenter: Monzr M. Al Malki, M.D., City of Hope Director of Unrelated Donor BMT Program
and Haploidentical Transplant Program, Assistant Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation
 
Publication Number: 472
Type: Oral
Session Name: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Clinical Studies in Hodgkin Lymphoma
Session Date and Time: Sunday, Dec. 6, 2020, 2 to 3:30 p.m. ET
Presentation Time: 2:30 p.m.
Presenter: Alex Herrera, M.D., City of Hope Assistant Professor, Department of Hematology & Hematopoietic Cell Transplantation
 
Publication Number: 192
Type: Oral
Session Name: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Transplant Toxicities
Session Date and Time: Saturday, Dec. 5, 2020, Noon to 1:30 p.m. ET
Presentation Time: 12:45 p.m.
Presenter: Anthony S. Stein, M.D., City of Hope Associate Director, Gehr Family Center for Leukemia Research; Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation
 
Publication Number: 75
Type: Oral
Session Name: 732. Clinical Allogeneic Transplantation: Results I
Session Date and Time: Saturday, Dec. 5, 2020, 7:30 to 9 a.m. ET
Presentation Time: 7:30 a.m.
Study Co-chair: Ryotaro Nakamura, M.D., City of Hope Director, Center for Stem Cell Transplantation; Professor, Department of Hematology & Hematopoietic Cell Transplantation
 
# # #
 
About City of Hope
City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases. Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy. City of Hope’s translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin and numerous breakthrough cancer drugs are based on technology developed at the institution. A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope has been ranked among the nation’s “Best Hospitals” in cancer by U.S. News & World Report for 14 consecutive years. Its main campus is located near Los Angeles, with additional locations throughout Southern California. For more information about City of Hope, follow us on FacebookTwitterYouTube or Instagram.
Tags